MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2026.03.042

Медицинская библиотека · Transplantation and cellular therapy · 2026

Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.

Arai Yasuyuki, Ohbiki Marie, Kurata Mio, Ota Shuichi, Tanaka Masatsugu, Imada Kazunori, Fukuda Takahiro, Katayama Yuta, Doki Noriko, Kanda Yoshinobu, Sakata-Yanagimoto Mamiko, Onodera Koichi, Hiramoto Nobuhiro, Asada Noboru, Ishida Takashi, Uchida Hiroki, Uno Satoshi, Teshima Takanori, Takami Akiyoshi, Konuma Takaaki, Yanada Masamitsu, Atsuta Yoshiko, Yano Shingo

СтатьяПеревод в очереди

Аннотация

The FLT3 inhibitor, gilteritinib, has been widely used in patients with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). However, its tolerability and effectiveness after allogeneic hematopoietic stem cell transplantation (HSCT) are not well known outside of clinical trials. Therefore, we performed nationwide surveillance in Japan. We used data from the national registry for patients receiving transplants, including R/R FLT3-mutated AML patients treated with gilteritinib before and/or after HSCT. Post-HSCT administration dosage and safety were summarized, and outcomes, including relapse-free survival (RFS) were investigated. We also used the historical cohort of HSCT before the approval of gilteritinib. Among R/R FLT3-mutated AML patients, 120 were treated with gilteritinib before and/or after allo-HSCT, and maintenance treatment was performed in 55 patients. The median initiation day was Day 47 after allo-HSCT (range, 23-379), with a median starting dose of 80 mg (range, 40-120 mg). Serious adverse events leading to gilteritinib dose reduction or temporary discontinuation were observed in 52.7% of these cases. The 3-year RFS was 46.8% and patients treated with post-HSCT gilteritinib had significantly better RFS (58.8%) than those without it (36.4%) (P < .001). Survival data in the historical cohort were similar to that of those who did not resume gilteritinib. In the subgroup analysis, post-HSCT gilteritinib showed an RFS benefit in cord blood transplantation (79.4% vs. 26.1%, P < .001) but not in bone marrow or peripheral blood stem cell transplantation. This Japanese real-world study supports the tolerability and effectiveness of post-HSCT gilteritinib in R/R FLT3-mutated AML.

Для цитирования: Arai Yasuyuki, Ohbiki Marie, Kurata Mio, Ota Shuichi, Tanaka Masatsugu, Imada Kazunori, Fukuda Takahiro, Katayama Yuta, Doki Noriko, Kanda Yoshinobu, Sakata-Yanagimoto Mamiko, Onodera Koichi, Hiramoto Nobuhiro, Asada Noboru, Ishida Takashi, Uchida Hiroki, Uno Satoshi, Teshima Takanori, Takami Akiyoshi, Konuma Takaaki, Yanada Masamitsu, Atsuta Yoshiko, Yano Shingo. Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.. Transplantation and cellular therapy. 2026. DOI: 10.1016/j.jtct.2026.03.042.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.